Praxis Precision Medicines (PRAX) Profit After Tax (2019 - 2026)

Praxis Precision Medicines' Profit After Tax history runs 8 years deep, the most recent figure standing at -$92.6 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 33.63% year-over-year to -$92.6 million in Q1 2026; TTM through Mar 2026 was -$326.6 million, a 53.65% decrease from a year earlier, with the FY2025 full-year figure at -$303.3 million, down 65.9% from the prior year.
• Profit After Tax slipped to -$92.6 million in Q1 2026 per PRAX's latest filing, from -$88.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$24.6 million in Q3 2023 and bottomed at -$92.6 million in Q1 2026.
• The 5-year median for Profit After Tax is -$51.9 million (2024), against an average of -$53.9 million.
• Across the five-year window, Profit After Tax tumbled 151.04% in 2022 and surged 45.49% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$41.2 million in 2022, then jumped by 34.72% to -$26.9 million in 2023, then tumbled by 118.32% to -$58.7 million in 2024, then slumped by 51.58% to -$88.9 million in 2025, then declined by 4.11% to -$92.6 million in 2026.
• Per Business Quant, the three latest PRAX Profit After Tax figures stand at -$92.6 million (Q1 2026), -$88.9 million (Q4 2025), and -$73.9 million (Q3 2025).